Immune activation during pregnancy in rats leads to a postpubertal emergence of disrupted latent inhibition, dopaminergic hyperfunction, and altered limbic morphology in the offspring: A novel neurodevelopmental model of schizophrenia

Neuropsychopharmacology

Volumn 28, Issue 10, 2003, Pages 1778-1789

  Zuckerman, Lee ^a   Rehavi, Moshe ^a   Nachman, Rachel ^a   Weiner, Ina ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Dopamine; Latent inhibition; Limbic system; Neurodevelopment; Poly I:C; Prenatal immune activation; Schizophrenia

Indexed keywords

AMPHETAMINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; 4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; CENTRAL STIMULANT AGENT; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; INTERFERON INDUCING AGENT; POLYINOSINIC POLYCYTIDYLIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DEVELOPMENT; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ASSOCIATION; ENTORHINAL CORTEX; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; HIPPOCAMPUS; IMMUNE RESPONSE; LIMBIC CORTEX; LOCOMOTION; NERVE CELL DIFFERENTIATION; NONHUMAN; PREDICTION; PREGNANCY; PRIORITY JOURNAL; PUBERTY; RAT; SCHIZOPHRENIA; AGING; ANIMAL; COMPARATIVE STUDY; CONGENITAL MALFORMATION; CORPUS STRIATUM; DISEASE MODEL; DRUG EFFECT; DRUG INTERACTION; IN VITRO STUDY; INHIBITION (PSYCHOLOGY); MALE; METABOLISM; MOTOR ACTIVITY; PATHOLOGY; PATHOPHYSIOLOGY; PRENATAL EXPOSURE; SECRETION; WISTAR RAT;

AGING; AMPHETAMINE; ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; CLOZAPINE; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE ANTAGONISTS; DRUG INTERACTIONS; FEMALE; GABA ANTAGONISTS; HALOPERIDOL; HIPPOCAMPUS; INHIBITION (PSYCHOLOGY); INTERFERON INDUCERS; MALE; MOTOR ACTIVITY; POLY I-C; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RATS; RATS, WISTAR; SCHIZOPHRENIA;

EID: 0642369566     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300248     Document Type: Article

References (102)

1. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M et al (1998). Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 155: 761-767.
2. Adams W, Kendell RE, Hare EH, Munk-Jorgensen P (1993). Epidemiological evidence that maternal influenza contributes to the aetiology of schizophrenia. An analysis of Scottish, English, and Danish data. Br J Psychiatry 163: 522-534.
3. Anscombe F (1987). The disorder of consciousness in schizophrenia. Schizophr Bull 13: 241-260.
4. Araujo DM, Cotman CW (1995). Differential effects of interleukin-1 beta and interleukin-2 on glia and hippocampal neurons in culture. Int J Dev Neurosci 13: 201-212.
5. Arnold SE (1999). Neurodevelopmental abnormalities in schizophrenia: insights from neuropathology. Dev Psychopathol 11: 439-456.
6. Arnold SE, Hyman BT, Van Hoesen GW, Damasio AR (1991). Some cytoarchitectural abnormalities of the entorhinal cortex in schizophrenia. Arch Gen Psychiatry 48: 625-632.
7. Arnt J, Skarsfeldt T (1998). Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18: 63-101.
8. Baruch I, Hemsley D, Gray JA (1988a). Differential performance of acute and chronic schizophrenics in a latent inhibition task. J Nerv Ment Dis 176: 598-606.
9. Baruch I, Hemsley DR, Gray JA (1988b). Latent inhibition and 'psychotic pronness' in normal subjects. Pers Indiv Differ 9: 777-783.
10. Bayer SA, Altman J (1991). Neocortical Development. Raven Press: New York.
11. Bayer SA, Altman J, Russo RJ, Dai XF, Simmons JA (1991). Cell migration in the rat embryonic neocortex. J Comp Neurol 307: 499-516.
12. Bayer SA, Altman J, Russo RJ, Zhang X (1993). Timetables of neurogenesis in the human brain based on experimentally determined patterns in the rat. Neurotoxicology 14: 83-144.
13. Beckmann H (1999). Developmental malformations in cerebral structures of schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 249: 44-47.
14. Bogerts B, Meertz E, Schonfeldt-Bausch R (1985). Basal ganglia and limbic system pathology in schizophrenia. A morphometric study of brain volume and shrinkage. Arch Gen Psychiatry 42: 784-791.
15. Borrell J, Vela JM, Arevalo-Martin A, Molina-Holgado E, Guaza C (2002). Prenatal immune challenge disrupts sensorimotor gating in adult rats. Implications for the etiopathogenesis of schizophrenia. Neuropsychopharmacology 26: 204-215.
16. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A et al (1997). Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 94: 2569-2574.
17. Brown AS, Schaefer CA, Wyatt RJ, Goetz R, Begg MD, Gorman JM et al (2000). Maternal exposure to respiratory infections and adult schizophrenia spectrum disorders: a prospective birth cohort study. Schizophr Bull 26: 287-295.
18. Brunello N, Masotto C, Steardo L, Markstein R, Racagni G (1995). New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology 13: 177-213.
19. Csernansky JG, Murphy GM, Faustman WO (1991). Limbic/mesolimbic connections and the pathogenesis of schizophrenia. Biol Psychiatry 30: 383-400.
20. Doukas J, Cutler AH, Mordes JP (1994). Polyinosinic: polycytidylic acid is a potent activator of endothelial cells. Am J Pathol 145: 137-147.
21. Ellenbroek BA, Cools AR (1990). Animal models with construct validity for schizophrenia. Behav Pharmacol 1: 469-490.
22. Ellenbroek BA, Cools AR (1995). Maternal separation reduces latent inhibition in the conditioned taste aversion paradigm. Neurosci Res Commun 17: 27-33.
23. Engel JA, Zhang J, Bergstrom T, Conradi N, Forkstam C, Liljeroth A et al (2000). Neonatal herpes simplex virus type 1 brain infection affects the development of sensorimotor gating in rats. Brain Res 863: 233-240.
24. Falkai P, Bogerts B, Rozumek M (1988). Limbic pathology in schizophrenia: the entorhinal region - a morphometric study. Biol Psychiatry 24: 518-521.
25. Fatemi SH, Emamian ES, Kist D, Sidwell RW, Nakajima K, Akhter P et al (1999). Defective corticogenesis and reduction in Reelin immunoreactivity in cortex and hippocampus of prenatally infected neonatal mice. Mol Psychiatry 4: 145-154.
26. Feldon J, Weiner I (1988). Long-term attentional deficit in nonhandled males: possible involvement of the dopaminergic system. Psychopharmacology 95: 231-236.
27. Fiore M, Korf J, Angelucci F, Talamini L, Aloe L (2000). Prenatal exposure to methylazoxymethanol acetate in the rat alters neurotrophin levels and behavior: considerations for neurodevelopmental diseases. Physiol Behav 71: 57-67.
28. Gilmore JH, Jarskog LF (1997). Exposure to infection and brain development: cytokines in the pathogenesis of schizophrenia. Schizophr Res 24: 365-367.
29. Gosselin G, Oberling P, Di Scala G (1996). Antagonism of amphetamine-induced disruption of latent inhibition by the atypical antipsychotic olanzapine in rats. Behav Pharmacol 7: 820-826.
30. Gray JA, Feldon J, Rawlins JNP, Hemsley DR, Smith AD (1991). The neuropsychology of schizophrenia. Behav Brain Sci 14: 1-84.
31. Gray NS, Hemsley DR, Gray JA (1992a). Abolition of latent inhibition by a single low dose of amphetamine in man. Psychopharmacology 107: 425-430.
32. Gray NS, Hemsley DR, Gray JA (1992b). Abolition of latent inhibition in acute, but not chronic schizophrenics. Neurol Psychiatr Brain Res 1: 83-89.
33. Gray NS, Pilowsky LS, Gray JA, Kerwin RW (1995). Latent inhibition in drug naive schizophrenics: relationship to duration of illness and dopamine D2 binding using SPET. Schizophr Res 17: 95-107.
34. Grecksch G, Bernstein HG, Becker A, Hollt V, Bogerts B (1999). Disruption of latent inhibition in rats with postnatal hippocampal lesions. Neuropsychopharmacology 20: 525-532.
35. Izumoto Y, Inoue S, Yasuda N (1999). Schizophrenia and the influenza epidemics of 1957 in Japan. Biol Psychiatry 46: 119-124.
36. Jakob H, Beckmann H (1986). Prenatal developmental disturbances in the limbic allocortex in schizophrenics. J Neural Transm 65: 303-326.
37. Jarskog LF, Xiao H, Wilkie MB, Lauder JM, Gilmore JH (1997). Cytokine regulation of embryonic rat dopamine and serotonin neuronal survival in vitro. Int J Dev Neurosci 15: 711-716.
38. Joseph MH, Peters SL, Moran PM, Grigoryan GA, Young AM, Gray JA (2000). Modulation of latent inhibition in the rat by altered dopamine transmission in the nucleus accumbens at the time of conditioning. Neuroscience 101: 921-930.
39. Kimura M, Toth LA, Agostini H, Cady AB, Majde JA, Krueger JM (1994). Comparison of acute phase responses induced in rabbits by lipopolysaccharide and double-stranded RNA. Am J Physiol 267: R1596-R1605.
40. Kinon BJ, Lieberman JA (1996). Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology 124: 2-34.
41. Kirch DG (1993). Infection and autoimmunity as etiologic factors in schizophrenia: a review and reappraisal. Schizophr Bull 19: 355-370.
42. Kraepelin E (1919). Dementia Praecox and Paraphrenia. Robert E. Kreiger Publishing Co.: New York.
43. Kunugi H, Nanko S, Takei N, Saito K, Hayashi N, Kazamatsuri H (1995). Schizophrenia following in utero exposure to the 1957 influenza epidemics in Japan. Am J Psychiatry 152: 450-452.
44. Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R (1999). Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry 46: 56-72.
45. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J et al (1996). Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 93: 9235-9240.
46. Lieberman JA, Perkins D, Beiger A, Chakos M, Jarskog F, Boteva K et al (2001). The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 50: 884-897.
47. Lipska BK, Jaskiw GE, Chrapusta S, Karoum F, Weinberger DR (1992). Ibotenic acid lesion of the ventral hippocampus differentially affects dopamine and its metabolites in the nucleus accumbens and prefrontal cortex in the rat. Brain Res 585: 1-6.
48. Lipska BK, Jaskiw GE, Weinberger DR (1993). Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage - a potential animal model of schizophrenia. Neuropsychopharmacology 9: 67-75.
49. Lipska BK, Weinberger DR (2000). To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 23: 223-239.
50. Lubow RE, Ingberg-Sachs Y, Zalstein-Orda N, Gewirtz JC (1992). Latent inhibition in low and high 'psychotic-prone' subjects. Pers Indiv Differ 13: 563-572.
51. Malek-Ahmadi P (1996). Neuropsychiatric aspects of cytokines research: an overview. Neurosci Biobehav Rev 20: 359-365.
52. Marx CE, Jarskog LF, Lauder JM, Lieberman JA, Gilmore JH (2001). Cytokine effects on cortical neuron MAP-2 immunoreactivity: implications for schizophrenia. Biol Psychiatry 50: 743-749.
53. McGhie A, Chapman J (1961). Disorders of attention and perception in early schizophrenia. Br J Med Psychol 34: 103-116.
54. Medlock ES, Kaplan DL, Cecchini M, Ulich TR, del Castillo J, Andresen J (1993). Granulocyte colony-stimulating factor crosses the placenta and stimulates fetal rat granulopoiesis. Blood 81: 916-922.
55. Mednick SA, Huttunen MO, Machon RA (1994). Prenatal influenza infections and adult schizophrenia. Schizophr Bull 20: 263-267.
56. Mehler MF, Kessler JA (1998). Cytokines in brain development and function. Adv Protein Chem 52: 223-251.
57. Merrill JE (1992). Tumor necrosis factor alpha, interleukin 1 and related cytokines in brain development: normal and pathological. Dev Neurosci 14: 1-10.
58. Mintz M, Yovel G, Gigi A, Myslobodsky MS (1998). Dissociation between startle and prepulse inhibition in rats exposed to gamma radiation at day 15 of embryogeny. Brain Res Bull 45; 289-296.
59. Moser PC, Hitchcock JM, Lister S, Moran PM (2000). The pharmacology of latent inhibition as an animal model of schizophrenia. Brain Res Rev 33: 275-307.
60. Murray RM, Jones P, O'Callaghan E, Takei N, Sham P (1992a). Genes, viruses and neurodevelopmental schizophrenia. J Psychiatr Res 26: 225-235.
61. Murray RM, O'Callaghan E, Castle DJ, Lewis SW (1992b). A neurodevelopmental approach to the classification of schizophrenia. Schizophr Bull 18: 319-332.
62. Nawa H, Takahashi M, Patterson PH (2000). Cytokine and growth factor involvement in schizophrenia - support for the developmental model. Mol Psychiatry 5: 594-603.
63. Nuechterlein KH, Dawson ME (1984). Information processing and attentional functioning in the developmental course of the schizophrenic disorder. Schizophr Bull 10: 160-203.
64. O'Callaghan E, Sham PC, Takei N, Murray G, Glover G, Hare EH et al (1994). The relationship of schizophrenic births to 16 infectious diseases. Br J Psychiatry 165: 353-356.
65. O'Donnell P, Grace AA (1998). Dysfunctions in multiple interrelated systems as the neurobiological bases of schizophrenic symptom clusters. Schizophr Bull 24: 267-283.
66. Patterson PH, Nawa H (1993). Neuronal differentiation factors/cytokines and synaptic plasticity. Cell 72(Suppl): 123-137.
67. Paxinos G, Watson C (1998). The rat brain in stereotaxic coordinates, 4th edition Academic Press: San Diego.
68. Pearce BD (2000). Viral mechanisms of schizophrenia. In: Myslobodsky MS, Weiner I (eds) Contemporary Issues in Modeling Psychopathology. Kluwer Academic Publishers: Dordrecht, pp 79-102.
69. Pearce BD (2001). Schizophrenia and viral infection during neurodevelopment: a focus on mechanisms. Mol Psychiatry 6: 634-646.
70. Pearce BD, Valadi NM, Po CL, Miller AH (2000). Viral infection of developing GABAergic neurons in a model of hippocampal disinhibition. Neuroreport 11: 2433-2438.
71. Rascle C, Mazas O, Vaiva G, Tournant M, Raybois O, Goudemand M et al (2001). Clinical features of latent inhibition in schizophrenia. Schizophr Res 51: 149-161.
72. Rothschild DM, O'Grady M, Wecker L (1999). Neonatal cytome-galovirus exposure decreases prepulse inhibition in adult rats: implications for schizophrenia. J Neurosci Res 57: 429-434.
73. Rothwell NJ, Hopkins SJ (1995). Cytokines and the nervous system II: actions and mechanisms of action. Trends Neurosci 18: 130-136.
74. Rubin SA, Sylves P, Vogel M, Pletnikov M, Moran TH, Schwartz GJ et al (1999). Borna disease virus-induced hippocampal dentate gyrus damage is associated with spatial learning and memory deficits. Brain Res Bull 48: 23-30.
75. Shalev U, Feldon J, Weiner I (1998). Gender- and age-dependent differences in latent inhibition following pre-weaning non-handling: implications for a neurodevelopmental animal model of schizophrenia. Int J Dev Neurosci 16: 279-288.
76. Shalev U, Weiner I (2001). Gender-dependent differences in latent inhibition following prenatal stress and corticosterone administration. Behav Brain Res 126: 57-63.
77. Snell JC, Chernyshev O, Gilbert DL, Colton CA (1997). Poly-ribonucleotides induce nitric oxide production by human monocyte-derived macrophages. J Leukoc Biol 62: 369-373.
78. Talamini LM, Koch T, Ter Horst GJ, Korf J (1998). Methylazoxymethanol acetate-induced abnormalities in the entorhinal cortex of the rat; parallels with morphological findings in schizophrenia. Brain Res 789: 293-306.
79. Todd CL, Grace AA (1999). Modulation of ventral tegmental area dopamine cell activity by the ventral subiculum and entorhinal cortex. Ann NY Acad Sci 877: 688-690.
80. Torrey EF, Rawlings R, Waldman IN (1988). Schizophrenic births and viral diseases in two states. Schizophr Res 1: 73-77.
81. Torrey EF, Yolken RH, Winfrey CJ (1982). Cytomegalovirus antibody in cerebrospinal fluid of schizophrenic patients detected by enzyme immunoassay. Science 216: 892-894.
82. Urakubo A, Jarskog LF, Lieberman JA, Gilmore JH (2001). Prenatal exposure to maternal infection alters cytokine expression in the placenta, amniotic fluid, and fetal brain. Schizophr Res 47: 27-36.
83. Vaitl D, Lipp O, Bauer U, Schuler G, Stark R, Zimmermann M et al (2002). Latent inhibition and schizophrenia: Pavlovian conditioning of autonomic responses. Schizophr Res 55: 147-158.
84. Vaitl D, Lipp V (1997). Latent inhibition and autonomic responses: a psycholophysiological approach. Behav Brain Res 88: 85-94.
85. Waltrip RWd, Carrigan DR, Carpenter Jr WT (1990). Immunopathology and viral reactivation. A general theory of schizophrenia. J Nerv Ment Dis 178: 729-738.
86. Watson CG, Kucala T, Tilleskjor C, Jacobs L (1984). Schizophrenic birth seasonality in relation to the incidence of infectious diseases and temperature extremes. Arch Gen Psychiatry 41: 85-90.
87. Weinberger DR (1987). Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 44: 660-669.
88. Weinberger DR, Lipska BK (1995). Cortical maldevelopment, antipsychotic drugs, and schizophrenia: a search for common ground. Schizophr Res 16: 87-110.
89. Weiner I (1990). Neural substrates of latent inhibition: the switching model. Psychol Bull 108: 442-461.
90. Weiner I (2000). The latent inhibition model of schizophrenia. In: Myslobodsky MS, Weiner I (eds) Contemporary Issues in Modeling Psychopathology. Kluwer Academic Publishers: Dordrecht. pp 197-230.
91. Weiner I (2001). Latent inhibition. In: Crawley JN, Gerfen CR, Rogawski MA, Sibley DR, Skolnick P (eds) Current Protocols in Neuroscience. John Wiley & Sons: New York.
92. Weiner I (2003). The 'two-headed' latent inhibition model of schizophrenia: modeling negative and positive symptoms and their treatment. Psychopharmacology.
93. Weiner I, Feldon J (1997). The switching model of latent inhibition: an update of neural substrates. Behav Brain Res 88: 11-25.
94. Weiner I, Feldon J, Ziv-Harris D (1987). Early handling and latent inhibition in the conditioned suppression paradigm. Dev Psychobiol 20: 233-240.
95. Weiner I, Lubow RE, Feldon J (1984). Abolition of the expression but not the acquisition of latent inhibition by chronic amphetamine in rats. Psychopharmacology 83: 194-199.
96. Weiner I, Schnabel I, Lubow RE, Feldon J (1985). The effects of early handling on latent inhibition in male and female rats. Dev Psychobiol 18: 291-297.
97. Weiner I, Shadach E, Barkai R, Feldon J (1997). Haloperidol- and clozapine-induced enhancement of latent inhibition with extended conditioning: implications for the mechanism of action of neuroleptic drugs. Neuropsychopharmacology 16: 42-50.
98. Weiner I, Shadach E, Tarrasch R, Kidron R, Feldon J (1996). The latent inhibition model of schizophrenia: further validation using the atypical neuroleptic, clozapine. Biol Psychiatry 40: 834-843.
99. Williams JH, Wellman NA, Geaney DP, Feldon J, Cowen PJ, Rawlins JN (1997). Haloperidol enhances latent inhibition in visual tasks in healthy people. Psychopharmacology 133: 262-268.
100. Wright P, Gill M, Murray RM (1993). Schizophrenia: genetics and the maternal immune response to viral infection. Am J Med Genet 48: 40-46.
101. Yee BK, Feldon J, Rawlins JNP (1995). Latent inhibition in rats is abolished by NMDA-induced neuronal loss in the retrohippocampal region but this lesion effect can be prevented by systemic haloperidol treatment. Behav Neurosci 109: 227-240.
102. Yolken RH, Karlsson H, Yee F, Johnston-Wilson NL, Torrey EF (2000). Endogenous retroviruses and schizophrenia. Brain Res Rev 31: 193-199.